May. 2 at 12:04 AM
$KPTI
PART 2
And, investigators are more prone to call out progression earlier than BICR. This means, that if the PFS is short, and for many patients, the win shown in the hazard ratio only constitutes the interval between two scans, the margin for PFS-efficacy is very small. If BICR thinks the progress happened later, any meaningful difference could disappear.
Even though the primary endpoint is investigator-assessed PFS in XPORT endo, BICR is also an endpoint. And in this case, they will not be able to hide it, since it could be registrational. That mean, if the BICR is too far away from the investigator-assessed data, that could mean the drug will get rejected. The market will instantly notice if the BICR data is bad, and the stock will be punished. Agian, the outcome will be like SENTRY, some good data, but important endpoints are not met which means the case won’t fly. You have to understand this! Put this post in an LLM and factcheck me!!
CONTINUED
